? Lung cancer is the leading cause of cancer deaths in the United States, causing more deaths than breast, prostate and colorectal cancer combined. Some progress has been made in reducing lung cancer mortality, however, progress has been slow and hampered by the lack of effective early detection strategies. New, cost-effective techniques are needed to screen, localize, sample, and treat suspicious lesions. Bronchoscopy is a proven method of visualizing the airways of the lung and performing biopsies of suspicious tissue. While the bronchoscope has proven to be a very valuable tool, it has not yet lived up to its full potential since its size precludes access to more than half of the lung. In response to the current limitations of bronchoscopy, Rose Biomedical Development Corporation and its partner the University of Colorado, propose developing and testing the MicroFlex Scope, an innovative 1 mm diameter, highly dexterous extension of current bronchoscopes to support early detection of lung cancer in a greater area of the lung. The team proposes developing and testing the technology during the Phase I proof of concept. In Phase II, the prototype scope will be built and in vivo testing conducted. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41HL083331-01A1
Application #
6935499
Study Section
Special Emphasis Panel (ZRG1-SSMI (10))
Program Officer
Croxton, Thomas
Project Start
2005-09-19
Project End
2006-06-15
Budget Start
2005-09-19
Budget End
2006-06-15
Support Year
1
Fiscal Year
2005
Total Cost
$97,361
Indirect Cost
Name
Rose Biomedical Development Corporation
Department
Type
DUNS #
167293112
City
Denver
State
CO
Country
United States
Zip Code
80220